CRBU (Caribou Biosciences) Total Payout Ratio: (As of Sep. 21, 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

CRBU Caribou Biosciences Inc CRBU
61 GF Score
Price $1.33
GF Value $1.45
Valuation Fairly Valued
! 5 Warning Signs
View Full Analysis

What is Caribou Biosciences Total Payout Ratio?

Total Payout Ratio is the percent a company has paid to its shareholders through net repurchase of shares and dividends based on its Net Income.

Caribou Biosciences's current Total Payout Ratio is .

Caribou Biosciences Total Payout Ratio Related Terms

Caribou Biosciences Total Payout Ratio Historical Data

* Premium members only.

The historical data trend for Caribou Biosciences's Total Payout Ratio can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Caribou Biosciences Total Payout Ratio Chart

Caribou Biosciences Annual Data
Trend Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Total Payout Ratio
Get a 7-Day Free Trial - - - - -

Caribou Biosciences Quarterly Data
Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26 Jun26
Total Payout Ratio Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only - - - - -

CRBU vs CDXS, SPRB, MENS: Total Payout Ratio Comparison

For the Biotechnology subindustry, Caribou Biosciences's Total Payout Ratio, along with its competitors' market caps and Total Payout Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Caribou Biosciences Total Payout Ratio vs Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Caribou Biosciences's Total Payout Ratio distribution charts can be found below:

* The bar in red indicates where Caribou Biosciences's Total Payout Ratio falls into.


CRBU
61GF Score
Caribou Biosciences Inc CRBU
Total Payout Ratio is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Caribou Biosciences Total Payout Ratio Calculation

Total Payout Ratio is a measurement showing the proportion of earnings a company pays shareholders in the form of dividends and net stock repurchases.

Caribou Biosciences's Total Payout Ratio for the fiscal year that ended in Dec. 2025 is calculated as

Total Payout Ratio=- (Repurchase of Stock + Issuance of Stock + Cash Flow for Dividends) / Net Income
=- (-0 + 4.821 + -0) / -148.125
=0.03

Caribou Biosciences's Total Payout Ratio for the quarter that ended in Jun. 2026 is calculated as

Total Payout Ratio=- (Repurchase of Stock + Issuance of Stock + Cash Flow for Dividends) / Net Income
=- (-0 + 17.936 + -0) / -24.282
=0.74

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Is Caribou Biosciences (CRBU) Overvalued in 2026?

Based on GuruFocus' analysis, Caribou Biosciences stock appears to be undervalued. The current stock price of $1.33 is trading 8.3% below its estimated GF Value™ of $1.45. GuruFocus considers Caribou Biosciences to be Fairly Valued.

Key valuation signals for CRBU:

  • Total Payout Ratio:
  • GF Value™: $1.45 vs. price of $1.33 (8.3% below fair value)
  • GF Score™: 61/100 with 5 warning signs

No single metric tells the full story. See the CRBU stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Caribou Biosciences Business Description

Address 2929 7th Street, Suite 105, Berkeley, CA, USA, 94710
Caribou Biosciences Inc is a clinical-stage Clustered Regularly Interspaced Short Palindromic Repeats (CRISPR) genome-editing biopharmaceutical company dedicated to developing transformative therapies for patients with devastating diseases. The company is focused on advancing two clinical-stage allogeneic CAR-T cell therapy product candidates for the treatment of patients with hematologic malignancies: Vispacabtagene regedleucel and CB-011. It operates in one reportable segment, which is the business of developing allogeneic CAR-T cell therapies. Geographically, it operates in the United States and the rest of the World, of which the United States derives the maximum revenue.
61GF Score

Get the complete analysis for CRBU

Total Payout Ratio is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$1.33
Price
$1.45
GF Value